Kolotkin RL, Williams VSL, von Huth Smith L, Meincke HH, Qin S, Williams N, Fehnel SE. Confirmatory psychometric evaluations of the impact of weight on quality of life-lite clinical trials version (IWQOL-Lite-CT). Clin Obes. 2021 Oct;11(5):e12477. doi: 10.1111/cob.12477
Ervin CM, Whalley D, von Huth Smith L, Crawford R, Dine J, Fehnel SE. Development of the impact of weight on daily activities questionnaire: a patient-reported outcome measure. Clin Obes. 2020 Dec;10(6):e12387. doi: 10.1111/cob.12387
Kolotkin RL, Williams VSL, Ervin CM, Williams N, Meincke HH, Qin S, von Huth Smith L, Fehnel SE. Validation of a new measure of quality of life in obesity trials: impact of weight on quality of life-lite clinical trials version. Clin Obes. 2019 Jun;9(3):e12310. doi: 10.1111/cob.12310
Goyal RK, Tzivelekis S, Rothman KJ, Candrilli SD, Kaye JA. Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer. Support Care Cancer. 2018 Feb;26(2):539-48. doi: 10.1007/s00520-017-3863-9
Hauber AB, Mange B, Price MA, Wolin D, Bensink M, Kaye JA, Chandler D. Administration options for pegfilgrastim prophylaxis: patient and physician preferences from a cross-sectional survey. Support Care Cancer. 2018 Jan;26(1):251-60. doi: 10.1007/s00520-017-3841-2
Kolotkin RL, Ervin CM, Meincke HH, Hojbjerre L, Fehnel SE. Development of a clinical trials version of the Impact of Weight on Quality of Life–Lite questionnaire (IWQOL-Lite Clinical Trials Version): results from two qualitative studies. Clin Obes. 2017 Oct;7(5):290-9. doi: 10.1111/cob.12197
Marion S, Tzivelekis S, Darden C, Price MA, Sherif B, Garcia J, Kaye JA, Chandler D. "Same-day" administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale. Support Care Cancer. 2016 Sep;24(9):3889-96. doi: 10.1007/s00520-016-3193-3